CIK治疗恶性肿瘤的研究进展及临床应用现状  

The anti-tumor development of CIK and its clinical application

作　　者：聂鑫[1] 刘侃峰[1] 滕少侠[1] 

机构地区：[1]辽宁省沈阳市中国医科大学,110001

出　　处：《中国实用医药》2007年第7期106-108,共3页China Practical Medicine

摘　　要：用免疫活性细胞输注的过继免疫是肿瘤生物治疗的研究热点之一。此疗法不仅是常规抗肿瘤治疗的补充,更是为晚期不宜手术或无法承受放疗化疗所带来的副作用的患者开辟了一个新的治疗途径,成为人类抗击肿瘤最有希望的战略措施之一。CIK(Cytokine Induced Killer)是继LAK,TIL及CD3AK细胞之后,具有细胞增殖倍数高、肿瘤杀伤能力强等特点的新一代过继免疫抗肿瘤细胞。本文就CIK的特点,抗肿瘤机制,及临床应用现状等作一综述。Objective adoptive immunotherapy is one of the hotest subject in biotherapy of tumor. This treatment is not only the supplement to conventional therapy, but also apply hope to people who can not sustain the side effects of radiotherapy and chemotherapy any longer. CIK is a new generation of adoptive immunocell .It has strong ability of proliferation, and high efficiency in killing different tumor cells than LAK,TIL and CD3AK cells. This review is focused on the character, anti-tumor mechanism, and clinical application of CIK.

关 键 词：CIK 过继免疫 肿瘤治疗 

分 类 号：R730.5[医药卫生—肿瘤]